Ignite Creation Date:
2024-05-05 @ 11:24 AM
Last Modification Date:
2024-10-26 @ 9:06 AM
Study NCT ID:
NCT00024167
Status:
TERMINATED
Last Update Posted:
2016-03-22
First Post:
2001-09-13
Brief Title:
Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer
Sponsor:
MD Anderson Cancer Center
Organization:
MD Anderson Cancer Center
Study Overview
Official Title:
A Prospective Randomized Phase III Trial Comparing Consolidation Therapy With or Without Strontium-89 Following Induction Chemotherapy in Androgen-Independent Prostate Cancer
Status:
TERMINATED
Status Verified Date:
2016-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Terminated due to slow accrual
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die Radioactive substances such as strontium-89 may relieve bone pain associated with prostate cancer It is not yet known whether chemotherapy is more effective with or without strontium-89 in treating bone metastases
PURPOSE This randomized phase III trial is studying giving chemotherapy together with strontium-89 to see how well it works compared to chemotherapy alone in treating patients with prostate cancer that has spread to the bone
PURPOSE This randomized phase III trial is studying giving chemotherapy together with strontium-89 to see how well it works compared to chemotherapy alone in treating patients with prostate cancer that has spread to the bone
Detailed Description:
OBJECTIVES
Compare the effectiveness in terms of overall survival of consolidation therapy with or without strontium chloride Sr 89 after induction chemotherapy in patients with androgen-independent prostate cancer
OUTLINE This is a randomized study Patients are stratified according to type of induction chemotherapy KAVE vs prednisone and docetaxel number of bony metastases no more than 20 vs more than 20 Eastern Cooperative Oncology ECOG performance status 0-1 vs 2-3 and use of zoledronate yes vs no
Induction therapy Patients receive 1 of 2 induction therapy regimens
Regimen A KAVE Patients receive doxorubicin IV over 24 hours on day 1 and oral ketoconazole three times daily on days 1-7 of weeks 1 3 and 5 Patients receive vinblastine IV over 30 minutes on day 1 and oral estramustine three times daily on days 1-7 of weeks 2 4 and 6 Patients receive no treatment on weeks 7 and 8 Treatment repeats every 8 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity
NOTE Patients continue to receive oral ketoconazole three times daily until disease progression
Regimen B prednisone and docetaxel Patients receive oral prednisone twice daily on days 1-21 days 1-14 of course 5 only and docetaxel IV over 1 hour on day 1 Treatment repeats every 21 days for at least 5 courses in the absence of disease progression or unacceptable toxicity
Consolidation therapy Patients with a prostate-specific antigen PSA response at least 50 decline in PSA level from baseline at week 16 OR at least 2 PSA levels decreased at least 50 from baseline are randomized to 1 of 2 consolidation treatment arms
Arm I Patients receive doxorubicin IV over 24 hours once weekly for 6 weeks plus strontium chloride Sr 89 IV once at the beginning of chemotherapy
Arm II Patients receive doxorubicin as in arm I Patients are followed every 4 weeks until PSA progression and then every 3 months thereafter
PROJECTED ACCRUAL Approximately 480 patients 240 randomized will be accrued for this study within 48 months
Compare the effectiveness in terms of overall survival of consolidation therapy with or without strontium chloride Sr 89 after induction chemotherapy in patients with androgen-independent prostate cancer
OUTLINE This is a randomized study Patients are stratified according to type of induction chemotherapy KAVE vs prednisone and docetaxel number of bony metastases no more than 20 vs more than 20 Eastern Cooperative Oncology ECOG performance status 0-1 vs 2-3 and use of zoledronate yes vs no
Induction therapy Patients receive 1 of 2 induction therapy regimens
Regimen A KAVE Patients receive doxorubicin IV over 24 hours on day 1 and oral ketoconazole three times daily on days 1-7 of weeks 1 3 and 5 Patients receive vinblastine IV over 30 minutes on day 1 and oral estramustine three times daily on days 1-7 of weeks 2 4 and 6 Patients receive no treatment on weeks 7 and 8 Treatment repeats every 8 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity
NOTE Patients continue to receive oral ketoconazole three times daily until disease progression
Regimen B prednisone and docetaxel Patients receive oral prednisone twice daily on days 1-21 days 1-14 of course 5 only and docetaxel IV over 1 hour on day 1 Treatment repeats every 21 days for at least 5 courses in the absence of disease progression or unacceptable toxicity
Consolidation therapy Patients with a prostate-specific antigen PSA response at least 50 decline in PSA level from baseline at week 16 OR at least 2 PSA levels decreased at least 50 from baseline are randomized to 1 of 2 consolidation treatment arms
Arm I Patients receive doxorubicin IV over 24 hours once weekly for 6 weeks plus strontium chloride Sr 89 IV once at the beginning of chemotherapy
Arm II Patients receive doxorubicin as in arm I Patients are followed every 4 weeks until PSA progression and then every 3 months thereafter
PROJECTED ACCRUAL Approximately 480 patients 240 randomized will be accrued for this study within 48 months
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| U10CA045809 | NIH | None | None |
| P30CA016672 | NIH | None | None |
| MDA-ID-00156 | OTHER | None | None |
| NCI-3410 | None | None | None |
| CDR0000068897 | REGISTRY | None | None |
| NCI-2009-00009 | REGISTRY | NCI CTRP | httpsreporternihgovquickSearchP30CA016672 |